Description
Pazopanib is the third tyrosine kinase inhibitor (TKI) and the sixth targeted therapy that has received US FDA approval for the treatment of advanced or metastatic RCC. The primary mechanism of action of pazopanib in RCC is through its antiangiogenic properties via inhibition of the intracellular tyrosine kinase of vascular endothelial growth factor receptor and platelet-derived growth factor receptor.
PAZINIB400mg Tablet is a protein kinase inhibitor used in the treatment of kidney cancer and soft tissue sarcoma
Reviews
There are no reviews yet.